Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Page 1 de 93 résultats
Treatment of tumors by arginine deprivation
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention generally relates to a method for the treatment of tumors, the apparatus for such a method of treatment, and the compositions used in such method of treatment. In particular, the present invention relates to a method for the treatment of tumors by
Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
COPYRIGHT NOTICE/PERMISSION
A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the Patent and
Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to an enzyme, arginine deiminase. In particular, it relates to a unique arginine deiminase isolated from mycoplasmas. More particularly, the invention is directed to a mycoplasmal proteinase K resistant arginine deiminase and to a method of preparing
Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
STATEMENT REGARDING SEQUENCE LISTING
The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is POLA_005_01US_SeqList_ST25.txt.
Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the field of methods and compositions for the treatment of hypotension. The invention also relates to the field of combination therapeutic regimens particularly those which include a regimen of a particularly
Use of arginine vasopressin receptor antagonists for the treatment of prostate cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present disclosure is directed to materials and methods for the treatment of prostate cancer.
INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY
Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted
Arginine-rich anti-vascular endothelial growth factor peptides that inhibit growth and metastasis of human tumor cells by blocking angiogenesis
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention relates to a novel peptide that shows inhibitory activity of the vascular endothelial growth factor (hereinafter, referred to as "VEGF"), which is an angiogenic factor, and the use thereof for the prophylaxis and treatment of cancers and
Protein arginine N-methyltransferase-5 method of cancer treatment
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a national stage filing under 35 U.S.C. .sctn.371 of PCT/GB2010/052163, filed on 20 Dec. 2010 which in turn claims priority to United Kingdom Patent Application No. GB 0922332.2, filed on 22 Dec. 2009. The disclosures of each of the
Protein Arginine Deiminase inhibitors as novel therapeutics for rheumatoid arthritis and cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND
Protein Arginine Deiminases (PADs) are calcium dependant enzymes that catalyze the hydrolytic conversion of arginine residues to citrulline residues in a variety of protein substrates as illustrated in FIG. 1. While the five known members of this family, PADs 1, 2, 3, 4, and 6, share a
N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The invention refers to N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic according to claim 1, methods for producing the tetrapeptide derivatives according to the present invention in accordance with the independent claims 18 and 23, a pharmaceutical according to
Erythrocytes containing arginine deiminase
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The present invention relates to the depletion of plasma arginine, to compositions for providing said depletion and to the treatment of pathologies that may benefit from said depletion and its effects, for example on the synthesis of nitric oxide. Thus, the invention relates to the treatment of
Erythrocytes containing arginine deiminase
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The present invention relates to the depletion of plasma arginine, to compositions for providing said depletion and to the treatment of pathologies that may benefit from said depletion and its effects, for example on the synthesis of nitric oxide. Thus, the invention relates to the treatment of
Arginine decomposing enzyme therapeutic composition
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention generally relates to a therapeutic composition and a method for the treatment of cancer, and more particularly to a therapeutic composition comprising an arginine decomposing enzyme and a method of its administration for the treatment of cancer. In
Mutated form of arginine deiminase
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention is directed to mutations of arginine deiminase for more efficient production and processing and thus improved treatment of cancer and other disease states.
BACKGROUND OF THE INVENTION
It is presently believed that the amino acid arginine may play an
Methods of treatment with arginine deiminase
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
STATEMENT REGARDING SEQUENCE LISTING
The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is POLA_001_02US_ST25.txt. The text
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
